

Resource Summary Report

Generated by [dkNET](#) on Aug 7, 2026

c-Myc (D84C12) XP Rabbit mAb

RRID:AB_1903938

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 5605, RRID:AB_1903938

Antibody Information

URL: http://antibodyregistry.org/AB_1903938

Proper Citation: Cell Signaling Technology Cat# 5605, RRID:AB_1903938

Target Antigen: c-Myc (D84C12) XP Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IF-IC, F. Consolidation on 10/2018: AB_10484409, AB_10858578, AB_1903938.

Antibody Name: c-Myc (D84C12) XP Rabbit mAb

Description: This monoclonal targets c-Myc (D84C12) XP Rabbit mAb

Target Organism: dg, rat, porcine, h, canine, m, mouse, r, pg, human, mk

Antibody ID: AB_1903938

Vendor: Cell Signaling Technology

Catalog Number: 5605

Record Creation Time: 20250820T030320+0000

Record Last Update: 20250820T151331+0000

Ratings and Alerts

- Used for immunocytochemistry by the Human Islet Research Network community.
Contact(s): [Peng Wang](#), [Andrew Stewart](#) - Human Islets Research Network

No alerts have been found for c-Myc (D84C12) XP Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 187 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#).

Entrialgo-Cadierno R, et al. (2026) Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma. *Cancer cell*, 44(6), 1218.

Wang Q, et al. (2026) FANCA-dependent FEN1 recruitment suppresses transcription-replication conflicts and PARPi sensitivity. *Molecular cell*.

Ferrick KR, et al. (2026) Transient proliferation by reversible YAP and mitogen control of the cyclin D1/p27 ratio. *Communications biology*, 9(1).

Fleming AM, et al. (2026) Developmental reprogramming underlies chemotherapy resistance in favorable-histology Wilms tumor. *Cell reports*, 45(3), 117063.

Ding J, et al. (2026) CDC20 promotes prostate cancer progression via modulating c-MYC and PI3K-AKT signaling. *iScience*, 29(7), 116409.

Matsuura K, et al. (2026) Distinct metabolic dependency on BCAA defines cancer stemness and malignancy in human triple-negative breast cancer. *Cell reports*, 45(7), 117630.

Brunner HL, et al. (2026) A multivalent adaptor mechanism drives the nuclear import of proteasomes. *Nature communications*, 17(1).

Lesire L, et al. (2026) Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin-degrading enzyme, a new molecular vulnerability in multiple myeloma. *British journal of pharmacology*, 183(12), 3355.

Priebe V, et al. (2026) TCF3::HLF orchestrates an enhancer-promoter network with activation of MEF2C to promote immature HSC gene expression in leukemia. *Science advances*, 12(19), eadu3728.

Kral AJ, et al. (2026) Splice-switching ASOs targeting the AURKA 5' UTR collapse an SRSF1-AURKA-MYC oncogenic circuit in pancreatic cancer. *Molecular cell*, 86(1), 60.

Sunami T, et al. (2026) IGF2BP3 is essential for the growth heterogeneity of colorectal adenoma cells by regulating MYC. *iScience*, 29(7), 116535.

Bernardi F, et al. (2026) Multiomic integration reveals tumoral heterogeneity of lipid dependence within lethal group 3 medulloblastoma. *Cancer cell*.

Calderon-Aparicio A, et al. (2026) S6K1 Modulates STAT3 Activation to Promote Resistance to Radiotherapy in Lung Cancer. *International journal of molecular sciences*, 27(4).

Mitra T, et al. (2026) MEK-dependent bioenergetic demand drives terminal CD8⁺ T cell exhaustion. *Immunity*.

Li G, et al. (2025) Microenvironmental γ -TrCP negates amino acid transport to trigger CD8⁺ T cell exhaustion in human non-small cell lung cancer. *Cell reports*, 44(1), 115128.

Zhang D, et al. (2025) CHI-KAT8i5 suppresses ESCC tumor growth by inhibiting KAT8-mediated c-Myc stability. *Cell reports*, 44(1), 115135.

Theardy MS, et al. (2025) Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. *Cell reports. Medicine*, 6(8), 102253.

Mitra T, et al. (2025) MEK-dependent bioenergetic demand drives terminal CD8⁺ T cell exhaustion. *bioRxiv : the preprint server for biology*.

Harper NW, et al. (2025) RNA Pol II inhibition activates cell death independently from the loss of transcription. *Cell*.

Montuori G, et al. (2025) Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers. *Cancer discovery*, 15(10), 2054.